The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)

摘要: BACKGROUND AND PURPOSE: Gadobenate dimeglumine (MultiHance) has higher r1 relaxivity than gadoterate meglumine (Dotarem) which may permit the use of lower doses for MR imaging applications. Our aim was to compare 0.1- and 0.05-mmol/kg body weight gadobenate with 0.1-mmol/kg assessment brain tumors. MATERIALS METHODS: We performed crossover, intraindividual comparison (Arm 1) 2). Adult patients suspected or known tumors were randomized Arm 1 (70 patients) 2 (107 underwent identical examinations at 1.5T. The agents injected in randomized-sequence order, separated by 2–14 days. scanners, sequences (T1-weighted spin-echo T1-weighted high-resolution gradient-echo), acquisition timing examinations. Three blinded readers evaluated images diagnostic information (degree definition lesion extent, border delineation, visualization internal morphology, contrast enhancement) quantitatively percentage enhancement lesion-to-background ratio. Safety assessments performed. RESULTS: In 1, a highly significant superiority (P .1) observed any reader end point, exception CONCLUSIONS: Significantly superior morphologic are demonstrated on compared gadoterate. No meaningful differences recorded between